2011 was a busy year and biosimilars was the hot topic of the year for GaBI Online.
Top 10 most read GaBI Online articles in 2011
Home/Pharma News
|
Posted 30/03/2012
0
Post your comment
To ensure that none of GaBI Online’s readers have missed out on what happened in 2011, below is a list of the top 10 most read articles in 2011. Follow the links in the titles of each article to remind you what happened over the last year.
*arranged in top 10 order with the most read article listed first
This shows that guidelines are the issues of most interest, followed by a general interest in news and current status around biosimilars development, for instance, opportunities, challenges and approval status around the globe (Brazil, China, Europe). Needless to say, scientific research data is one of the most popular articles within GaBI Online.
If you are interested in contributing a research article in a similar area to GaBI Journal, please send us your submission here.
GaBI’s mission – building trust in cost-effective treatments
Editor’s comment
What do you think about GaBI Online providing overviews of this type? Please feel free to share your thoughts via email or in the comments section below. What other overviews would you like to see?
Guidelines
Advances in EMA plans to streamline biosimilar assessment
FDA issues guidance on AI use in drug and biologicals regulatory decision making
Policies & Legislation
ANVISA and Danish Medicines Agency renew health regulatory collaboration
Colombia and Brazil introduce reforms to enhance healthcare regulation
Colombia boosts health sovereignty through public-private biotech collaboration agreement

Home/Pharma News Posted 07/04/2025
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment